A Phase 3 interventional study of GW685698X in Rhinitis, Vasomotor, sponsored by GlaxoSmithKline. Completed at 53 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GW685698X
Drug: GW685698X
Aqueous Nasal Spray 100mcg
Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)
The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom scores for rhinorrhea, nasal congestion and postnasal drip where each symptom was scored on a scale of 0 (no symptoms) to 3 (severe symptoms).. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS)
The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from baseline was calculated as endpoint value minus the baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Number of Participants With Overall Evaluation of Response to Therapy
The overall evaluation of Response to Therapy was based on a 7-point categorical scale where the participants rated their perception of the change or lack of change in their VMR (Vasomotor rhinitis) symptoms at the end of the study. The 7 categories were: 1=significantly improved, 2=moderately improved, 3= mildly improved, 4= no change, 5= mildly worse, 6= moderately worse, and 7= significantly worse.
Time frame: Up to 4 weeks
Mean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS
The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. Change from Baseline was calculated as post randomization value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the PM (PM rTNSS). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS
The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments.The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS
The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Individual Daily, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Post-nasal Drip
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The daily reflective nasal symptom scores was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Pre-dose, Instantaneous, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
The AM, pre-dose, instantaneous nasal symptom score is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Change From Baseline Over the Entire Treatment Period in Individual PM, Reflective, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and was performed in the PM (PM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Mean Scores Changes From Baseline as a Function of Time
The onset of treatment effect was assessed by the mean change from Baseline in AM iTNSS (Days 1 to 28), the mean change from Baseline in daily rTNSS (Days 1 to 28), and mean change from Baseline in AM rTNSS and PM rTNSS. The time to maximum effect was also evaluated by the mean change from Baseline in daily rTNSS for Days 1 to 28. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
Time frame: Baseline (4 days prior to randomization [Day 1]) and Daily for 28 days
The actual dose delivered from the product was 27.5 micrograms (µg) /actuation, which is therefore proposed as the label claim rather than 25 µg/actuation. Based on this spray content assessment, the dose examined in this study was actually 110 µg rather than the 100 µg dose indicated in the protocol.
| Milestone | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Started | 173 | 179 |
| Completed | 160 | 167 |
| Not completed | 13 | 12 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Use of prohibited medicine | 1 | 2 |
| Withdrew: Early termination | 1 | 1 |
| Withdrew: Admisnitrative | 1 | 0 |
The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom scores for rhinorrhea, nasal congestion and postnasal drip where each symptom was scored on a scale of 0 (no symptoms) to 3 (severe symptoms).. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS) | -1.71 ± 0.16 | -2.05 ± 0.15 |
The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from baseline was calculated as endpoint value minus the baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS) | -1.48 ± 0.16 | -1.87 ± 0.16 |
The overall evaluation of Response to Therapy was based on a 7-point categorical scale where the participants rated their perception of the change or lack of change in their VMR (Vasomotor rhinitis) symptoms at the end of the study. The 7 categories were: 1=significantly improved, 2=moderately improved, 3= mildly improved, 4= no change, 5= mildly worse, 6= moderately worse, and 7= significantly worse.
| Participants | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Significantly Improved | 26 | 33 |
| Moderately Improved | 37 | 40 |
| Mildly Improved | 45 | 47 |
| No Change | 52 | 50 |
| Mildly Worse | 1 | 3 |
| Moderately Worse | 4 | 1 |
| Significantly Worse | 3 | 2 |
The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. Change from Baseline was calculated as post randomization value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS | -1.69 ± 0.16 | -2.04 ± 0.16 |
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the PM (PM rTNSS). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS | -1.77 ± 0.16 | -2.07 ± 0.15 |
The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments.The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Percent change in score | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS | -26.14 ± 2.45 | -30.65 ± 2.40 |
The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Percent change in score | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Mean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS | -21.09 ± 2.54 | -27.46 ± 2.50 |
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The daily reflective nasal symptom scores was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Rhinorrhea | -0.50 ± 0.06 | -0.62 ± 0.06 |
| Nasal Congestion | -0.68 ± 0.06 | -0.81 ± 0.06 |
| Post-nasal Drip | -0.51 ± 0.06 | -0.61 ± 0.06 |
The AM, pre-dose, instantaneous nasal symptom score is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Rhinorrhea | -0.44 ± 0.06 | -0.56 ± 0.06 |
| Nasal congestion | -0.54 ± 0.06 | -0.70 ± 0.06 |
| Post-nasal drip | -0.48 ± 0.06 | -0.60 ± 0.06 |
The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110mcg QD |
|---|---|---|
| Rhinorrhea | -0.48 ± 0.06 | -0.61 ± 0.06 |
| Nasal congestion | -0.65 ± 0.06 | -0.78 ± 0.06 |
| Post-nasal drip | -0.55 ± 0.06 | -0.64 ± 0.06 |
The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and was performed in the PM (PM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| Rhinorrhea | -0.53 ± 0.06 | -0.59 ± 0.06 |
| Nasal congestion | -0.73 ± 0.06 | -0.84 ± 0.06 |
| Post-nasal drip | -0.49 ± 0.06 | -0.59 ± 0.06 |
The onset of treatment effect was assessed by the mean change from Baseline in AM iTNSS (Days 1 to 28), the mean change from Baseline in daily rTNSS (Days 1 to 28), and mean change from Baseline in AM rTNSS and PM rTNSS. The time to maximum effect was also evaluated by the mean change from Baseline in daily rTNSS for Days 1 to 28. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).
| Score on scale | Placebo | Fluticasone Furoate 110 mcg QD |
|---|---|---|
| AM iTNSS Day 1 | -0.47 ± 0.16 | -0.92 ± 0.16 |
| AM iTNSS Day 2 | -0.69 ± 0.17 | -1.01 ± 0.17 |
| AM iTNSS Day 3 | -0.75 ± 0.18 | -1.14 ± 0.18 |
| AM iTNSS Day 4 | -0.96 ± 0.18 | -1.22 ± 0.18 |
| AM iTNSS Day 5 | -1.15 ± 0.20 | -1.45 ± 0.19 |
| AM iTNSS Day 6 | -1.01 ± 0.20 | -1.59 ± 0.19 |
| AM iTNSS Day 7 | -1.17 ± 0.20 | -1.55 ± 0.19 |
| AM iTNSS Day 8 | -1.38 ± 0.20 | -1.61 ± 0.20 |
| AM iTNSS Day 9 | -1.47 ± 0.20 | -1.66 ± 0.20 |
| AM iTNSS Day 10 | -1.31 ± 0.21 | -1.78 ± 0.21 |
| AM iTNSS Day 11 | -1.48 ± 0.22 | -1.66 ± 0.21 |
| AMiTNSS Day 12 | -1.52 ± 0.22 | -1.86 ± 0.21 |
| AM iTNSS Day 13 | -1.48 ± 0.22 | -1.83 ± 0.21 |
| AM iTNSS Day 14 | -1.72 ± 0.21 | -1.95 ± 0.20 |
| AM iTNSS Day 15 | -1.54 ± 0.21 | -1.92 ± 0.21 |
| AM iTNSS Day 16 | -1.56 ± 0.21 | -1.99 ± 0.21 |
| AM iTNSS Day 17 | -1.64 ± 0.22 | -2.20 ± 0.22 |
| AM iTNSS Day 18 | -1.75 ± 0.21 | -2.21 ± 0.21 |
| AM iTNSS Day 19 | -1.70 ± 0.21 | -2.33 ± 0.21 |
| AM iTNSS Day 20 | -1.89 ± 0.22 | -2.11 ± 0.21 |
| AM iTNSS Day 21 | -1.97 ± 0.22 | -2.26 ± 0.22 |
| AM iTNSS Day 22 | -1.73 ± 0.22 | -2.32 ± 0.22 |
| AM iTNSS Day 23 | -1.80 ± 0.23 | -2.27 ± 0.22 |
| AM iTNSS Day 24 | -1.93 ± 0.23 | -2.40 ± 0.22 |
| AM iTNSS Day 25 | -1.93 ± 0.22 | -2.36 ± 0.22 |
| AM iTNSS Day 26 | -2.10 ± 0.23 | -2.68 ± 0.22 |
| AM iTNSS Day 27 | -2.01 ± 0.23 | -2.49 ± 0.22 |
| AM iTNSS Day 28 | -1.96 ± 0.28 | -2.62 ± 0.26 |
| rTNSS Day 1 | -0.71 ± 0.16 | -0.93 ± 0.15 |
| rTNSS Day 2 | -0.91 ± 0.16 | -1.17 ± 0.16 |
| rTNSS Day 3 | -1.07 ± 0.17 | -1.38 ± 0.16 |
| rTNSS Day 4 | -1.15 ± 0.17 | -1.43 ± 0.16 |
| rTNSS Day 5 | -1.22 ± 0.17 | -1.35 ± 0.17 |
| rTNSS Day 6 | -1.21 ± 0.19 | -1.51 ± 0.18 |
| rTNSS Day 7 | -1.37 ± 0.19 | -1.66 ± 0.18 |
| rTNSS Day 8 | -1.58 ± 0.18 | -1.82 ± 0.18 |
| rTNSS Day 9 | -1.55 ± 0.20 | -1.92 ± 0.19 |
| rTNSS Day 10 | -1.60 ± 0.20 | -2.06 ± 0.19 |
| rTNSS Day 11 | -1.65 ± 0.20 | -1.96 ± 0.20 |
| rTNSS Day 12 | -1.81 ± 0.19 | -2.14 ± 0.19 |
| rTNSS Day 13 | -1.87 ± 0.20 | -2.12 ± 0.20 |
| rTNSS Day 14 | -1.83 ± 0.20 | -2.17 ± 0.20 |
| rTNSS Day 15 | -1.70 ± 0.20 | -2.11 ± 0.20 |
| rTNSS Day 16 | -1.82 ± 0.20 | -2.38 ± 0.20 |
| rTNSS Day 17 | -1.94 ± 0.21 | -2.53 ± 0.20 |
| rTNSS Day 18 | -2.21 ± 0.20 | -2.51 ± 0.20 |
| rTNSS Day 19 | -1.99 ± 0.20 | -2.44 ± 0.20 |
| rTNSS Day 20 | -2.16 ± 0.20 | -2.47 ± 0.20 |
| rTNSS Day 21 | -2.12 ± 0.21 | -2.54 ± 0.20 |
| rTNSS Day 22 | -2.01 ± 0.21 | -2.47 ± 0.21 |
| rTNSS Day 23 | -1.99 ± 0.21 | -2.30 ± 0.20 |
| rTNSS Day 24 | -2.12 ± 0.21 | -2.60 ± 0.20 |
| rTNSS Day 25 | -2.28 ± 0.22 | -2.44 ± 0.21 |
| rTNSS Day 26 | -2.25 ± 0.22 | -2.57 ± 0.21 |
| rTNSS Day 27 | -2.23 ± 0.22 | -2.51 ± 0.21 |
| rTNSS Day 28 | -1.93 ± 0.28 | -2.58 ± 0.26 |
| AM rTNSS Day 1 | -0.70 ± 0.18 | -1.02 ± 0.17 |
| AM rTNSS Day 2 | -0.97 ± 0.18 | -1.20 ± 0.17 |
| AM rTNSS Day 3 | -1.12 ± 0.18 | -1.37 ± 0.18 |
| AM rTNSS Day 4 | -1.11 ± 0.18 | -1.45 ± 0.18 |
| AM rTNSS Day 5 | -1.33 ± 0.19 | -1.48 ± 0.18 |
| AM rTNSS Day 6 | -1.30 ± 0.20 | -1.59 ± 0.20 |
| AM rTNSS Day 7 | -1.28 ± 0.21 | -1.69 ± 0.20 |
| AM rTNSS Day 8 | -1.74 ± 0.21 | -1.85 ± 0.20 |
| AM rTNSS Day 9 | -1.73 ± 0.21 | -1.94 ± 0.21 |
| AM rTNSS Day 10 | -1.65 ± 0.21 | -2.10 ± 0.20 |
| AM rTNSS Day 11 | -1.66 ± 0.21 | -1.96 ± 0.20 |
| AM rTNSS Day 12 | -1.82 ± 0.21 | -2.05 ± 0.20 |
| AM rTNSS Day 13 | -1.87 ± 0.22 | -2.06 ± 0.21 |
| AM rTNSS Day 14 | -1.84 ± 0.21 | -2.14 ± 0.20 |
| AM rTNSS Day 15 | -1.67 ± 0.22 | -2.15 ± 0.21 |
| AM rTNSS Day 16 | -1.75 ± 0.22 | -2.37 ± 0.21 |
| AM rTNSS Day 17 | -2.12 ± 0.22 | -2.62 ± 0.22 |
| AM rTNSS Day 18 | -2.22 ± 0.21 | -2.48 ± 0.21 |
| AM rTNSS Day 19 | -1.83 ± 0.22 | -2.37 ± 0.21 |
| AM rTNSS Day 20 | -2.18 ± 0.22 | -2.42 ± 0.22 |
| AM rTNSS Day 21 | -2.07 ± 0.22 | -2.64 ± 0.22 |
| AM rTNSS Day 22 | -2.02 ± 0.23 | -2.44 ± 0.22 |
| AM rTNSS Day 23 | -1.96 ± 0.23 | -2.17 ± 0.22 |
| AM rTNSS Day 24 | -2.03 ± 0.23 | -2.57 ± 0.22 |
| AM rTNSS Day 25 | -2.22 ± 0.23 | -2.45 ± 0.22 |
| AM rTNSS Day 26 | -2.19 ± 0.23 | -2.59 ± 0.23 |
| AM rTNSS Day 27 | -2.23 ± 0.23 | -2.54 ± 0.23 |
| AM rTNSS Day 28 | -1.82 ± 0.30 | -2.55 ± 0.27 |
| PM rTNSS Day 1 | -0.88 ± 0.20 | -0.97 ± 0.19 |
| PM rTNSS Day 2 | -0.91 ± 0.18 | -1.19 ± 0.17 |
| PM rTNSS Day 3 | -1.10 ± 0.19 | -1.39 ± 0.19 |
| PM rTNSS Day 4 | -1.17 ± 0.19 | -1.42 ± 0.19 |
| PM rTNSS Day 5 | -1.06 ± 0.19 | -1.29 ± 0.18 |
| PM rTNSS Day 6 | -1.13 ± 0.21 | -1.42 ± 0.20 |
| PM rTNSS Day 7 | -1.48 ± 0.20 | -1.64 ± 0.20 |
| PM rTNSS Day 8 | -1.34 ± 0.20 | -1.73 ± 0.19 |
| PM rTNSS Day 9 | -1.49 ± 0.21 | -1.89 ± 0.20 |
| PM rTNSS Day 10 | -1.58 ± 0.21 | -2.07 ± 0.21 |
| PM rTNSS Day 11 | -1.62 ± 0.22 | -2.02 ± 0.22 |
| PM rTNSS Day 12 | -1.86 ± 0.21 | -2.29 ± 0.21 |
| PM rTNSS Day 13 | -1.91 ± 0.22 | -2.18 ± 0.21 |
| PM rTNSS Day 14 | -1.85 ± 0.23 | -2.15 ± 0.22 |
| PM rTNSS Day 15 | -1.78 ± 0.22 | -2.15 ± 0.21 |
| PM rTNSS Day 16 | -1.84 ± 0.23 | -2.33 ± 0.22 |
| PM rTNSS Day 17 | -1.81 ± 0.22 | -2.51 ± 0.22 |
| PM rTNSS Day 18 | -2.22 ± 0.22 | -2.54 ± 0.23 |
| PM rTNSS Day 19 | -2.23 ± 0.21 | -2.53 ± 0.21 |
| PM rTNSS Day 20 | -2.17 ± 0.21 | -2.52 ± 0.20 |
| PM rTNSS Day 21 | -2.19 ± 0.23 | -2.48 ± 0.22 |
| PM rTNSS Day 22 | -2.03 ± 0.22 | -2.53 ± 0.22 |
| PM rTNSS Day 23 | -2.06 ± 0.23 | -2.41 ± 0.22 |
| PM rTNSS Day 24 | -2.25 ± 0.22 | -2.64 ± 0.21 |
| PM rTNSS Day 25 | -2.39 ± 0.23 | -2.42 ± 0.22 |
| PM rTNSS Day 26 | -2.31 ± 0.23 | -2.54 ± 0.22 |
| PM rTNSS Day 27 | -2.25 ± 0.23 | -2.54 ± 0.22 |
| PM rTNSS Day 28 | -2.07 ± 0.30 | -2.68 ± 0.28 |
Collected over AEs were collected from screening up to 32 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/173 (0%) | 0/173 (0%) | 65/173 (37.6%) |
| Fluticasone Furoate 110mcg QD | 0/179 (0%) | 0/179 (0%) | 61/179 (34.1%) |
| Event | Placebo | Fluticasone Furoate 110mcg QD |
|---|---|---|
| HeadacheNervous system disorders | 23/173 | 12/179 |
| NasopharyngitisInfections and infestations | 8/173 | 8/179 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/173 | 5/179 |
| DiarrhoeaGastrointestinal disorders | 0/173 | 5/179 |
| Upper respiratory tract infectionInfections and infestations | 4/173 | 1/179 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/173 | 4/179 |
| Sinus headacheNervous system disorders | 3/173 | 2/179 |
| Neck painMusculoskeletal and connective tissue disorders | 3/173 | 0/179 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/173 | 0/179 |
| DysmenorrhoeaReproductive system and breast disorders | 3/173 | 1/179 |
| Age, Continuous(Years) | Placebo | Fluticasone Furoate 110 mcg QD | Total |
|---|---|---|---|
| Mean | 45.0 ± 14.66 | 46.6 ± 16.77 | 45.8 ± 15.77 |
| Sex: Female, Male(Participants) | Placebo | Fluticasone Furoate 110 mcg QD | Total |
|---|---|---|---|
| Female | 122 | 125 | 247 |
| Male | 51 | 54 | 105 |
| Race (NIH/OMB)(Participants) | Placebo | Fluticasone Furoate 110 mcg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 10 |
| White | 163 | 169 | 332 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Jul 2005 to primary completion in Feb 2006, 6 months.
Results were first posted in Mar 2018, 12 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate
Rhinitis, Vasomotor